Calithera Biosciences Initiates Phase 1/2 Trial of Telaglenastat in Combination with the PARP Inhibitor Talazoparib
Calithera Biosciences Announces Clinical Trial Collaboration to Evaluate IBRANCE (palbociclib) and talazoparib in Combination with CB-839
Pharmaceutical Investing Calithera Biosciences Reports Fourth Quarter 2017 Financial Results and Recent Highlights
